By co-transduction of sgRegnase-1 lentivirus and control sgRNAs to OT-I cells, and adoptively transferring to B16 Ova melanoma-bearing mice, the significant roles of Regnase-1 and Batf in reshaping effector response of CD8+ T cells anti-tumour activity was broadly elucidated, together with the potential role of targeting PTPN2 and SOCS1 in improving therapeutic efficacy of REGNASE-1 ablated CD8+ T cells [123]. This evidence concerns the gene SOCS1 and neoplasm.